天智颗粒治疗血管性痴呆的Meta分析

• 药品评价-循证医学研究 • 上一篇下一篇

天智颗粒治疗血管性痴呆的Meta分析

王保和

天津中医药大学第二附属医院

收稿日期:2015-11-01 修回日期:2015-11-23 出版日期:2015-12-25 发布日期:2015-12-25
基金资助:
［基金项目］“十二五”国家重大科技专项“重大新药创制”平台建设项目“ 创新药物研究开发技术平台建设—心脑血管疾病中药新药临床评价技术平台及规范研究”（编号：2012ZX09303-010）

Meta-analysis on the Effect of Tianzhi Keli in Treatment of Vascular Dementia

王保和

Tianjin University of Traditional Chinese Medicine

Received:2015-11-01 Revised:2015-11-23 Online:2015-12-25 Published:2015-12-25

摘要/Abstract

摘要： 目的：评价天智颗粒治疗血管性痴呆（VaD）的有效性和安全性。方法：检索CNKI、Wanfang、VIP、CBM、MEDLINE、SCI Expanded、EMBase、PubMed数据库（检索日期截至2015年6月)，收集天智颗粒治疗血管性痴呆的临床研究文献。根据纳入标准和Cochrane系统评价员手册5.3版独立进行文献筛选和文献质量评价，RevMan 5.3软件进行Meta分析。结果：共纳入12项研究，研究病例1102例，12项研究的质量评价均为C级。Meta分析结果显示，天智颗粒临床治疗血管性痴呆的总体疗效与对照组比较有统计学意义[OR=2.66，95％CI(2.01，3.52)]。结论：天智颗粒对血管性痴呆具有一定的治疗作用。其确切的临床疗效信息尚待进一步设计严密、实施科学的大样本研究证实。

Abstract: Objective： To review the efficacy and safety of Tianzhi Keli in treatment of vascular dementia(VaD). Methods：The literature of randomized and controlled trials(RCT) about treatment of VaD with Tianzhi Keli were retrieved from CNKI， Wanfang， VIP， CBM， MEDLINE， SCI Expanded， EMBase， PubMed from Jan 1，2006 to Jun 30，2015， and at the same time the reference document were manually retrieved. After the quality of literature was reviewed and materials were extracted by independent reviewer， all data was given Meta analysis by using RevMan5.3 software. Results： There were 12RCT enclosed involving 1102 patients. Tianzhi Keli increased significantly the total effective rate in clinical curative effect and difference was statistically significant[OR=2.66，95％CI(2.01，3.52)]. Conclusion： Tianzhi Keli is a safe and effective Chinese patent medicine for treating VaD. As the limitation of the RCT in this study，high-quality and large-sample randomized， blinding and controlled trials designed according to consorts are required to prove and review its effect in the future.

王保和. 天智颗粒治疗血管性痴呆的Meta分析[J]. .

王保和. Meta-analysis on the Effect of Tianzhi Keli in Treatment of Vascular Dementia[J]. .